

UNIVERSITY OF CALIFORNIA
 LOS ALAMOS SCIENTIFIC LABORATORY
 (CONTRACT W-7405-ENG-36)
 P. O. Box 1663
 Los Alamos, New Mexico 87544

IN REPLY
 REFER TO: MP-DO

December 3, 1971

Dr. Max L. M. Boone
 Department of Radiology
 University of Arizona
 Tucson, Arizona 85721

REPOSITORY Yermantown RC
 COLLECTION 6793
 BOX No. 3/S, LOC. # 2194
 FOLDER M, N+S - 21 (1971)
LAMPF

Dear Max:

In the light of our discussions and your letter of November 17th, I have tried to understand how we might accommodate those uses of the biomedical channel which are not an integral part of the clinical trial program supervised by Dr. Kligerman and his staff at the UNM Medical School.

As a result of a conversation with Dr. Walter and the commitment of all of us to the National Facility concept of LAMPF the following points appear clear:

- 1) Since the negative pion channel is being built with NCI funds, NCI requirements must take first priority on beam time for that channel, but without penalty to DEM-sponsored work. The point is we have two sponsors, and somehow each must be satisfied.
- 2) NCI does not propose to supervise beam time allocations on their channel for activities other than those they sponsor.
- 3) I believe that there will be considerable amount of free time on subject channel for at least the first year or two of LAMPF operation.
- 4) Space has been left for a second channel which is not yet funded. This channel can be implemented at any time that funds become available.
- 5) I shall make sure that protons of variable energy will be available from the biomedical channel.
- 6) It is my hope, and I think that of the NCI management, as well as Dr. Kligerman, that the clinical trials include participation by as many centers as possible. In particular I hope that you will assume a prominent role in the overall program developed by Dr. Kligerman and the various committee who will advise him. I know that this is his desire.

1098766

- 7) You and other radiotherapists with programs supported by NCI will in no way be excluded from studies at the biomedical channel, even though your programs may be supplementary to the main clinical trial program conducted by Dr. Kligerman. We will of course rely on NCI to determine beam time priorities if this is at issue.
- 8) To the extent that beam time is available, programs under other than NCI and DEM sponsorship will be considered for beam time. To make beam time assignments for such programs I will rely heavily on the LAMPF Program Advisory Committee and on the subcommittee for biomedical applications.

Sincerely,



Louis Rosen

LR/ab

cc: Dr. Bill Walter
Dr. Morton Kligerman
Dr. Nathaniel Barr